News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
GlobeNewswire Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
AVITA Medical (RCEL) CFO David D. O'Toole amended a previous insider transaction, reporting the purchase of 2,000 shares of common stock at $3.97 per share on June 12, 2026. This amendment corrected the transaction code from "A" to "P". Following this purchase, O'Toole's directly โฆ
Avita Medical Inc. (RCEL) is identified as a strong momentum stock with a Zacks Rank of #2 (Buy) and a Momentum Style Score of B. The article highlights RCEL's significant short-term price increases, outperforming its industry and the S&P 500, along with positive earnings โฆ
A new study on Avita Medical's PermeaDerm product demonstrated a 70% reduction in treatment costs compared to cadaveric allografts for temporary wound coverage. The PermeaDerm-I study, a randomized controlled trial involving 40 patients across 11 burn centers, also showed comparable healing and safety results, โฆ
TD Cowen has increased its price target for Avita Medical (NASDAQ:RCEL) to $14.00 from $12.00, maintaining a Buy rating, citing enhanced confidence in PermeaDerm's commercial potential after positive clinical trial data and surgeon endorsements. The stock has surged 185% year-to-date, trading near its 52-week โฆ
AVITA Medical has announced positive results from its PermeaDerm study, showing a significant 70% economic advantage over allograft for full-thickness wounds. The study also demonstrated comparable clinical outcomes to allograft, positioning PermeaDerm as a cost-effective and clinically sound solution for wound care. These findings โฆ
BTIG has increased its price target for Avita Medical (NASDAQ:RCEL) to $11.00 from $7.00, maintaining a Buy rating, following positive results from the company's PermeaDerm-I study. This study demonstrated a significant economic advantage over allograft and comparable clinical outcomes, with PermeaDerm and Cohealyx expected โฆ
Avita Medical Inc. (NASDAQ:RCEL) has received a "Moderate Buy" consensus rating from analysts, with five out of seven recommending a buy. The average 12-month price target is $8.25. The company recently reported better-than-expected quarterly earnings and revenue, and insiders have purchased 35,200 shares in โฆ
AVITA Medical (RCEL [https://seekingalpha.com/symbol/RCEL]) traded higher on Tuesday after the wound care company said a randomized controlled clinical trial testing its biosynthetic wound matrix PermeaDerm across 11 U.S. burn centers succeeded. The trial for 40 patients with wounds involving up to 30% of their โฆ
Avita Medical Inc (NASDAQ: RCEL) has released positive results for its PermeaDerm-I clinical trial, showing its wound matrix is as effective as traditional allografts but 70% cheaper. Despite this, the company remains unprofitable and cash-flow negative, reflected in its high Price-to-Sales ratio. GuruFocus's GF โฆ
AVITA Medical announced that its PermeaDerm-I clinical study demonstrated a 70% reduction in treatment costs compared to cadaveric allograft while maintaining similar clinical outcomes. The study involved 40 patients across 11 U.S. burn centers, showing significant cost savings per percent total body surface area โฆ
Avita Medical (NASDAQ: RCEL) has increased its 2026 revenue guidance to $86 millionโ$89 million, up from $80 millionโ$85 million, after a strong second quarter where sales grew 18% year-over-year to $21.7 million. The wound-care company is also on track to achieve cash-flow breakeven in โฆ
Avita Medical (NASDAQ: RCEL) aims to achieve cash flow breakeven in Q4 2025, driven by strong revenue growth and disciplined operating expenses. The company has raised its 2025 revenue guidance to $86 millionโ$89 million and expects continued expansion for its wound care product portfolio, โฆ
Image source: The Motley Fool. DATE Thursday, Aug. 6, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Vice President of Investor Relations and Corporate Communications - Ben Atkins President and Chief Executive Officer - Cary G. Vance Chief Financial Officer - David O'Toole Need a โฆ
This article announces the filing of a Form 8K by Avita Medical Ltd, dated August 11. It's a brief report from Investing.com, typical of regulatory filing announcements. The article provides financial data for various indices, commodities, bonds, and shares, as well as a list โฆ
AVITA Medical Inc (ASX:AVH) shares reached a new 52-week high of AUD 2.30 on August 12, 2026, closing at AUD 2.28 after a 7.04% increase. The company's market capitalization was approximately AUD 381.9 million, with the stock trading near the top of its annual โฆ
Avita Medical (NASDAQ:RCEL) has amended its distribution and manufacturing agreements with Stedical Scientific, securing rights to expand PermeaDerm product distribution into Europe, the UK, and Australia. The agreement increases Avita Medical's revenue share from PermeaDerm sales and waives previous minimum payment requirements. This follows โฆ
Canaccord Genuity has increased its target price for Avita Medical (AVH.AU) by 52%, setting a new target of A$1.90 per share. This upgrade suggests a strong positive outlook from the analyst firm regarding Avita Medical's future performance.
AVITA Medical (NASDAQ: RCEL) will host an investor webinar briefing on August 12, 2026, at 4:00 p.m. Pacific Time (August 13, 2026, 9:00 a.m. AEST). President and CEO Cary Vance and CFO David OโToole will present financial and business highlights from the recent Q2 โฆ
AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) will host an investor webinar briefing and presentation on August 12, 2026, at 4:00 p.m. Pacific Time. The webinar will feature President and CEO Cary Vance and CFO David OโToole, covering second-quarter 2026 earnings and including a โฆ
This article analyzes AVITA Medical, Inc.'s path to profitability, focusing on analyst forecasts for its breakeven point and revenue growth. It highlights the company's expected strong revenue growth and significant earnings improvement in the coming years. The analysis also briefly touches on the importance โฆ
Bell Potter has upgraded Avita Medical (ASX:AVH) from a "Speculative Hold" to a "Speculative Buy" rating. This upgrade indicates a more positive outlook on the company's stock by the analyst firm.
VALENCIA, Calif., Aug. 09, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, invites shareholders and prospective investors to attend its investor webinar briefing and presentation by Cary Vance, President and Chief โฆ
Avita Medical (NASDAQ:RCEL) announced its quarterly earnings, beating analyst estimates with an adjusted loss of $0.25 per share on revenue of $21.7 million. The company's revenue increased 18% year-over-year, driven by strong RECELL sales, and management raised its 2026 revenue guidance. Avita Medical expects โฆ
AVITA Medical (NASDAQ: RCEL, ASX: AVH) announced its participation in the Canaccord Genuity 46th Annual Growth Conference in Boston from August 11โ13, 2026. President and CEO Cary Vance is scheduled to speak on August 12, 2026, at 8:00 a.m. Eastern Time. A live webcast โฆ
Search by ticker symbol or company name and select a result to open its chart.
Start typing to find a stock or ETF.
Choose one or more countries for market search, or include every covered market.
Currently searching United States